Peter Marks admits the FDA was surprised by some efficacy and durability issues in gene therapy - but thinks these will be just a 'bump in the road'. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
